Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.
Twenty-two acutely psychotic patients were rigorously assessed for psychopathology at baseline and after 14 days of neuroleptic treatment. The neuroleptic radioreceptor assay (NRRA) was used to determine serum neuroleptic concentrations. Serum neuroleptic concentration was significantly, nonlinearly related to changes in BPRS Total Score, and BPRS Factor Scores for Thought Disturbance and Anxiety-Depression. Clinical improvement was associated with intermediate (11-50, 51-126 ng/ml haloperidol equivalents) while poor clinical outcome was related to both low (less than or equal to 10 ng/ml) or high (greater than 125 ng/ml) serum levels. The results are discussed in terms of a possible "therapeutic window" for the neuroleptics and the implications this might have for clinical practice.
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000097:blood* / Q000627:therapeutic use; D001590:Benztropine / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005476:Fluphenazine / Q000097:blood / Q000627:therapeutic use; D006220:Haloperidol / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy; D011869:Radioligand Assay; D013888:Thiothixene / Q000097:blood / Q000627:therapeutic use
D014150:Antipsychotic Agents; D001590:Benztropine; D013888:Thiothixene; D006220:Haloperidol; D005476:Fluphenazine